Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Immunity to conserved viral antigens is an attractive approach to develop a universal vaccine against epidemic and pandemic influenza. A nucleoprotein (NP)-based vaccine has been explored and preliminary studies have shown promise. However, no study has explored the immunity and cross-protective efficacy of recombinant NP derived from Escherichia coli compared with recombinant vaccinia virus (Tiantan).
Recombinant NP protein (rNP) from influenza virus A/Jingke/30/95(H3N2) was obtained from E. coli and recombinant vaccinia virus (Tiantan) RVJ1175NP. Purified rNP without adjuvant and RVJ1175NP were used to immunize BALB/c mice intramuscularly. Humoral immune responses were detected by ELISA, while cell-mediated immune responses were measured by ex vivo IFN-γ ELISPOT and in vivo cytotoxicity assays. The cross-protective efficacy was assessed by a challenge with a heterosubtype of influenza virus A/PR/8/34(H1N1).
Our results demonstrate that a high dose (90 μg) of rNP induced NP-specific antibodies and T cell responses that were comparable with those of RVJ1175NP in mice. Importantly, the survival ratio (36, 73, and 78%) of the vaccinated mice after the influenza virus A/PR/8/34(H1N1) challenge was rNP vaccine dose-dependent (10, 30, and 90 μg, respectively), and no significant differences were observed between the rNP- and RVJ1175NP-immunized (91%) mice.
Influenza A virus NP derived from E. coli or recombinant vaccinia (Tiantan) virus elicited cross-protection against influenza virus in mice, and the immune response and protective efficacy of rNP were comparable to RVJ1175NP. These data provide a basis for the use of prokaryotically expressed NP as a candidate universal influenza vaccine.
AuthorsBaoying Huang, Wenling Wang, Renqing Li, Xiuping Wang, Tao Jiang, Xiangrong Qi, Yingying Gao, Wenjie Tan, Li Ruan
JournalVirology journal (Virol J) Vol. 9 Pg. 322 ( 2012) ISSN: 1743-422X [Electronic] England
PMID23272943 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Viral
  • Influenza Vaccines
  • NP protein, Influenza A virus
  • RNA-Binding Proteins
  • Recombinant Proteins
  • Vaccines, Synthetic
  • Viral Core Proteins
  • Animals
  • Antibodies, Viral (immunology)
  • Cross Protection
  • Dose-Response Relationship, Drug
  • Enzyme-Linked Immunosorbent Assay
  • Escherichia coli (genetics, metabolism)
  • Female
  • Immunity, Cellular
  • Immunization Schedule
  • Influenza A Virus, H1N1 Subtype (genetics, immunology, metabolism)
  • Influenza A Virus, H3N2 Subtype (genetics, immunology, metabolism)
  • Influenza Vaccines (genetics, immunology, metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Orthomyxoviridae Infections (immunology, prevention & control)
  • Plasmids (genetics, metabolism)
  • RNA-Binding Proteins (genetics, immunology, metabolism)
  • Recombinant Proteins (genetics, immunology, metabolism)
  • Survival Analysis
  • Transformation, Genetic
  • Vaccination
  • Vaccines, Synthetic (immunology)
  • Vaccinia virus (genetics, metabolism)
  • Viral Core Proteins (genetics, immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: